# Daraxonrasib: RASolute 302 clinical evidence

A. Trial design and actual randomized arm sizes. B-C. Median overall and progression-free survival, with reported median confidence intervals and hazard ratios. D. Objective response rate with reported confidence intervals. E-F. Interpretation and selected safety warnings.

The figure uses the **overall randomized population**, not the RAS G12 subgroup. PFS and objective response were assessed by blinded independent central review. Reported percentages are not converted into exact patient counts. A median does not describe each individual trajectory. No Kaplan-Meier curve is inferred or reconstructed. Safety warnings are not a complete safety summary or a comparative safety analysis. NE means not estimable.

Source: [RASONQUE prescribing information, August 2026, Section 14 Table 6 and Sections 5-6](https://www.revmed.com/wp-content/uploads/2026/08/rasonque-pi.pdf). Regulatory context: [FDA, 26 August 2026](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-daraxonrasib-metastatic-pancreatic-adenocarcinoma).

Independent scientific communication example, not commissioned or endorsed by Revolution Medicines. Editable SVG, vector PDF and PNG derive from the same builder. Numeric data are included as JSON for traceability.